Risks from accidental exposures to engineered nanoparticles and neurological health effects: A critical review

Particle and Fibre Toxicology

Volumn 7, Issue , 2010, Pages

  Simkó, Myrtill ^a   Mattsson, Mats Olof ^b  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b AIT AUSTRIAN INSTITUTE OF TECHNOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM OXIDE; APOLIPOPROTEIN E; CADMIUM SELENIDE; CARBON NANOTUBE; CLAUDIN 5; IRON OXIDE; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; MANGANESE DIOXIDE; METAL NANOPARTICLE; NANOCARRIER; NANOPARTICLE; OCCLUDIN; POLYSORBATE 80; QUANTUM DOT; REACTIVE OXYGEN METABOLITE; RHODAMINE B; STREPTAVIDIN; TITANIUM DIOXIDE; ZINC; ZINC SULFIDE;

AEROBIC METABOLISM; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN DAMAGE; CATALYSIS; CELL LOSS; CELL VIABILITY; CENTRAL NERVOUS SYSTEM; CIRCULATION; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; GLIOSIS; HEALTH HAZARD; HUMAN; INTRACELLULAR SIGNALING; LIPID PEROXIDATION; LONG TERM EXPOSURE; MATERIAL STATE; NERVE CELL PLASTICITY; NERVE ENDING; NERVE FIBER TRANSPORT; NERVOUS SYSTEM FUNCTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RELATIVE BIOLOGIC EFFECTIVENESS; RESPIRATORY SYSTEM; REVIEW; RISK ASSESSMENT; STATIC ELECTRICITY; SYNAPTIC TRANSMISSION; AIR POLLUTANT; ANIMAL; BRAIN; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENVIRONMENTAL MONITORING; EXPOSURE; METABOLISM; PUBLIC HEALTH; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALIA;

AIR POLLUTANTS; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; ENVIRONMENTAL MONITORING; HUMANS; INHALATION EXPOSURE; NANOPARTICLES; PUBLIC HEALTH; RESPIRATORY SYSTEM; RISK ASSESSMENT;

EID: 78650298993     PISSN: None     EISSN: 17438977     Source Type: Journal    
DOI: 10.1186/1743-8977-7-42     Document Type: Review

References (88)

1. SCENIHR The scientific aspects of the existing and proposed definitions relating to products of nanoscience and nanotechnologies. 2007, SCENIHR., http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_012.pdf
2. Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG. Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol Sci 2007, 95:300-12. 10.1093/toxsci/kfl165, 17098817.
3. Borm PJ, Kelly F, Kunzli N, Schins RP, Donaldson K. Oxidant generation by particulate matter: from biologically effective dose to a promising, novel metric. Occup Environ Med 2007, 64:73-4. 10.1136/oem.2006.029090, 2078444, 17272658.
4. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006, 160:1-40. 10.1016/j.cbi.2005.12.009, 16430879.
5. Sohaebuddin SK, Thevenot PT, Baker D, Eaton JW, Tang L. Nanomaterial cytotoxicity is composition, size, and cell type dependent. Part Fibre Toxicol 2010, 7:22. 10.1186/1743-8977-7-22, 2936333, 20727197.
6. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005, 113:823-39. 10.1289/ehp.7339, 1257642, 16002369.
7. Thomas K, Sayre P. Research strategies for safety evaluation of nanomaterials, Part I: evaluating the human health implications of exposure to nanoscale materials. Toxicol Sci 2005, 87:316-21. 10.1093/toxsci/kfi270, 16049265.
8. De Jong WH, Borm PJ. Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine 2008, 3:133-49. 10.2147/IJN.S596, 2527668, 18686775.
9. Bhaskar S, Tian F, Stoeger T, Kreyling W, de la Fuente JM, Grazu V, Borm P, Estrada G, Ntziachristos V, Razansky D. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol 2010, 7:3. 10.1186/1743-8977-7-3, 2847536, 20199661.
10. Kniesel U, Wolburg H. Tight junctions of the blood-brain barrier. Cell Mol Neurobiol 2000, 20:57-76. 10.1023/A:1006995910836, 10690502.
11. Chen L, Yokel RA, Hennig B, Toborek M. Manufactured aluminum oxide nanoparticles decrease expression of tight junction proteins in brain vasculature. J Neuroimmune Pharmacol 2008, 3:286-95. 10.1007/s11481-008-9131-5, 2771674, 18830698.
12. Gao K, Jiang X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int J Pharm 2006, 310:213-9. 10.1016/j.ijpharm.2005.11.040, 16426779.
13. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2005, 2:108-19. 10.1602/neurorx.2.1.108, 539329, 15717062.
14. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 1995, 674:171-4. 10.1016/0006-8993(95)00023-J, 7773690.
15. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 2002, 10:317-25. 10.1080/10611860290031877, 12164380.
16. Tiwari SB, Amiji MM. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 2006, 3:219-32. 10.2174/156720106776359230, 16611008.
17. Calvo P, Gouritin B, Chacun H, Desmaele D, D'Angelo J, Noel JP, Georgin D, Fattal E, Andreux JP, Couvreur P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001, 18:1157-66. 10.1023/A:1010931127745, 11587488.
18. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, Buchel C, von Briesen H, Kreuter J. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release 2009, 137:78-86. 10.1016/j.jconrel.2009.03.002, 19285109.
19. Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci Nanotechnol 2004, 4:484-8. 10.1166/jnn.2003.077, 15503433.
20. Zheng G, Chen J, Li H, Glickson JD. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci USA 2005, 102:17757-62. 10.1073/pnas.0508677102, 1308912, 16306263.
21. Nagy Z, Peters H, Huttner I. Charge-related alterations of the cerebral endothelium. Lab Invest 1983, 49:662-71.
22. Hardebo JE, Kahrstrom J. Endothelial negative surface charge areas and blood-brain barrier function. Acta Physiol Scand 1985, 125:495-9. 10.1111/j.1748-1716.1985.tb07746.x, 4083048.
23. Fenart L, Casanova A, Dehouck B, Duhem C, Slupek S, Cecchelli R, Betbeder D. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J Pharmacol Exp Ther 1999, 291:1017-22.
24. Sahagun G, Moore SA, Hart MN. Permeability of neutral vs. anionic dextrans in cultured brain microvascular endothelium. Am J Physiol 1990, 259:H162-6.
25. Lockman PR, Koziara JM, Mumper RJ, Allen DD. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target 2004, 12:635-41. 10.1080/10611860400015936, 15621689.
26. Koziara JM, Lockman PR, Allen DD, Mumper RJ. The blood-brain barrier and brain drug delivery. J Nanosci Nanotechnol 2006, 6:2712-35. 10.1166/jnn.2006.441, 17048477.
27. Kim JS, Yoon TJ, Yu KN, Kim BG, Park SJ, Kim HW, Lee KH, Park SB, Lee JK, Cho MH. Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol Sci 2006, 89:338-47. 10.1093/toxsci/kfj027, 16237191.
28. Kim HR, Gil S, Andrieux K, Nicolas V, Appel M, Chacun H, Desmaele D, Taran F, Georgin D, Couvreur P. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol Life Sci 2007, 64:356-64. 10.1007/s00018-007-6390-x, 17256088.
29. Kreuter J. Drug targeting with nanoparticles. Eur J Drug Metab Pharmacokinet 1994, 19:253-6. 10.1007/BF03188928, 7867668.
30. Plard JP, Didier B. Comparison of the safety profiles of PLA50 and Me.PEG-PLA50 nanoparticles after single dose intravenous administration to rat. Colloids Surfaces B: Biointerfaces 1999, 16:173-183.
31. Wichmann HE, Spix C, Tuch T, Wolke G, Peters A, Heinrich J, Kreyling WG, Heyder J. Daily mortality and fine and ultrafine particles in Erfurt, Germany part I: role of particle number and particle mass. Res Rep Health Eff Inst 2000, 5-86. discussion 87-94..
32. Delfino RJ, Sioutas C, Malik S. Potential role of ultrafine particles in associations between airborne particle mass and cardiovascular health. Environ Health Perspect 2005, 113:934-46. 10.1289/ehp.7938, 1280331, 16079061.
33. Campbell A, Oldham M, Becaria A, Bondy SC, Meacher D, Sioutas C, Misra C, Mendez LB, Kleinman M. Particulate matter in polluted air may increase biomarkers of inflammation in mouse brain. Neurotoxicology 2005, 26:133-40. 10.1016/j.neuro.2004.08.003, 15527881.
34. Kleinman MT, Araujo JA, A N, Sioutas C, Campbell A, Cong PQ, H L, Bondy SC. Inhaled ultrafine particulate matter affects CNS inflammatory processes and may act via MAP kinase signaling pathways. Toxicol Lett 2008, 178:127-30. 10.1016/j.toxlet.2008.03.001, 2397447, 18420360.
35. Shin JA, Lee EJ, Seo SM, Kim HS, Kang JL, Park EM. Nanosized titanium dioxide enhanced inflammatory responses in the septic brain of mouse. Neuroscience 2010, 165:445-54. 10.1016/j.neuroscience.2009.10.057, 19892005.
36. Calderon-Garciduenas L, Franco-Lira M, Henriquez-Roldan C, Osnaya N, Gonzalez-Maciel A, Reynoso-Robles R, Villarreal-Calderon R, Herritt L, Brooks D, Keefe S, et al. Urban air pollution: influences on olfactory function and pathology in exposed children and young adults. Exp Toxicol Pathol 2010, 62:91-102. 10.1016/j.etp.2009.02.117, 19297138.
37. Valavanidis A, Fiotakis K, Vlachogianni T. Airborne particulate matter and human health: toxicological assessment and importance of size and composition of particles for oxidative damage and carcinogenic mechanisms. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2008, 26:339-62.
38. Oberdorster G, Sharp Z, Atudorei V, Elder A, Gelein R, Kreyling W, Cox C. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 2004, 16:437-45. 10.1080/08958370490439597, 15204759.
39. ICRP Human respiratory tract model for radiological protection. A report of a Task Group of the International Commission on Radiological Protection. Ann ICRP 1994, 24:1-482. ICRP.
40. Geiser M, Kreyling WG. Deposition and biokinetics of inhaled nanoparticles. Part Fibre Toxicol 2010, 7:2. 10.1186/1743-8977-7-2, 2826283, 20205860.
41. Kreyling WG, Blanchard JD, Godleski JJ, Haeussermann S, Heyder J, Hutzler P, Schulz H, Sweeney TD, Takenaka S, Ziesenis A. Anatomic localization of 24- and 96-h particle retention in canine airways. J Appl Physiol 1999, 87:269-84.
42. Moller W, Felten K, Meyer G, Meyer P, Seitz J, Kreyling WG. Corrections in dose assessment of 99 mTc radiolabeled aerosol particles targeted to central human airways using planar gamma camera imaging. J Aerosol Med Pulm Drug Deliv 2009, 22:45-54.
43. Schmid O, Moller W, Semmler-Behnke M, Ferron GA, Karg E, Lipka J, Schulz H, Kreyling WG, Stoeger T. Dosimetry and toxicology of inhaled ultrafine particles. Biomarkers 2009, 14(Suppl 1):67-73. 10.1080/13547500902965617, 19604063.
44. Muhlfeld C, Geiser M, Kapp N, Gehr P, Rothen-Rutishauser B. Re-evaluation of pulmonary titanium dioxide nanoparticle distribution using the "relative deposition index": Evidence for clearance through microvasculature. Part Fibre Toxicol 2007, 4:7. 10.1186/1743-8977-4-7, 2018701, 17727712.
45. Peters A, Veronesi B, Calderon-Garciduenas L, Gehr P, Chen LC, Geiser M, Reed W, Rothen-Rutishauser B, Schurch S, Schulz H. Translocation and potential neurological effects of fine and ultrafine particles a critical update. Part Fibre Toxicol 2006, 3:13. 10.1186/1743-8977-3-13, 1570474, 16961926.
46. Nemmar A, Hoet PH, Vanquickenborne B, Dinsdale D, Thomeer M, Hoylaerts MF, Vanbilloen H, Mortelmans L, Nemery B. Passage of inhaled particles into the blood circulation in humans. Circulation 2002, 105:411-4. 10.1161/hc0402.104118, 11815420.
47. Kreyling WG, Semmler M, Erbe F, Mayer P, Takenaka S, Schulz H, Oberdorster G, Ziesenis A. Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low. J Toxicol Environ Health A 2002, 65:1513-30. 10.1080/00984100290071649, 12396866.
48. Chen J, Tan M, Nemmar A, Song W, Dong M, Zhang G, Y L. Quantification of extrapulmonary translocation of intratracheal-instilled particles in vivo in rats: effect of lipopolysaccharide. Toxicology 2006, 222:195-201. 10.1016/j.tox.2006.02.016, 16584826.
49. Liu Y, Gao Y, Zhang L, Wang T, Wang J, Jiao F, Li W, Liu Y, Li Y, Li B, et al. Potential health impact on mice after nasal instillation of nano-sized copper particles and their translocation in mice. J Nanosci Nanotechnol 2009, 9:6335-43. 10.1166/jnn.2009.1320, 19908531.
50. Kreyling WG, Semmler-Behnke M, Seitz J, Scymczak W, Wenk A, Mayer P, Takenaka S, Oberdorster G. Size dependence of the translocation of inhaled iridium and carbon nanoparticle aggregates from the lung of rats to the blood and secondary target organs. Inhal Toxicol 2009, 21:55-60. 10.1080/08958370902942517, 19558234.
51. Mills NL, Amin N, Robinson SD, Anand A, Davies J, Patel D, de la Fuente JM, Cassee FR, Boon NA, Macnee W, et al. Do inhaled carbon nanoparticles translocate directly into the circulation in humans?. Am J Respir Crit Care Med 2006, 173:426-31. 10.1164/rccm.200506-865OC, 16339922.
52. Perry VH. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 2004, 18:407-13. 10.1016/j.bbi.2004.01.004, 15265532.
53. Cedervall T, Lynch I, Lindman S, Berggard T, Thulin E, Nilsson H, Dawson KA, Linse S. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA 2007, 104:2050-5. 10.1073/pnas.0608582104, 1892985, 17267609.
54. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA 2008, 105:14265-70. 10.1073/pnas.0805135105, 2567179, 18809927.
55. Oberdorster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med 2010, 267:89-105. 10.1111/j.1365-2796.2009.02187.x, 20059646.
56. Elder A, Gelein R, Silva V, Feikert T, Opanashuk L, Carter J, Potter R, Maynard A, Ito Y, Finkelstein J, et al. Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ Health Perspect 2006, 114:1172-8. 10.1289/ehp.9030, 1552007, 16882521.
57. Hunter DD, RD D. Identification and neuropeptide content of trigeminal neurons innervating the rat nasal epithelium. Neuroscience 1998, 83:591-9. 10.1016/S0306-4522(97)00324-2, 9460765.
58. Hunter DD, Undem BJ. Identification and substance P content of vagal afferent neurons innervating the epithelium of the guinea pig trachea. Am J Respir Crit Care Med 1999, 159:1943-8.
59. Elder A, Oberdorster G. Translocation and effects of ultrafine particles outside of the lung. Clin Occup Environ Med 2006, 5:785-96.
60. Yu LE, Lanry Yung L-Y, Ong C-N, Tan Y-L, Suresh Balasubramaniam K, Hartono D, Shui G, Wenk MR, Ong W-Y. Translocation and effects of gold nanoparticles after inhalation exposure in rats. Nanotoxicology 2007, 1:235-242.
61. Wang J, Liu Y, Jiao F, Lao F, Li W, Gu Y, Li Y, Ge C, Zhou G, Li B, et al. Time-dependent translocation and potential impairment on central nervous system by intranasally instilled TiO(2) nanoparticles. Toxicology 2008, 254:82-90. 10.1016/j.tox.2008.09.014, 18929619.
62. Sarkozi L, Horvath E, Konya Z, Kiricsi I, Szalay B, Vezer T, Papp A. Subacute intratracheal exposure of rats to manganese nanoparticles: Behavioral, electrophysiological, and general toxicological effects. Inhal Toxicol 2009, 21:83-91. 10.1080/08958370902939406, 19558238.
63. Viswaprakash N, Dennis JC, Globa L, Pustovyy O, Josephson EM, Kanju P, Morrison EE, Vodyanoy VJ. Enhancement of odorant-induced responses in olfactory receptor neurons by zinc nanoparticles. Chem Senses 2009, 34:547-57. 10.1093/chemse/bjp031, 19525316.
64. Wang J, Chen C, Liu Y, Jiao F, Li W, Lao F, Li Y, Li B, Ge C, Zhou G, et al. Potential neurological lesion after nasal instillation of TiO(2) nanoparticles in the anatase and rutile crystal phases. Toxicol Lett 2008, 183:72-80. 10.1016/j.toxlet.2008.10.001, 18992307.
65. Shimizu M, Tainaka H, Oba T, Mizuo K, Umezawa M, Takeda K. Maternal exposure to nanoparticulate titanium dioxide during the prenatal period alters gene expression related to brain development in the mouse. Part Fibre Toxicol 2009, 6:20. 10.1186/1743-8977-6-20, 2726979, 19640265.
66. Takeda K, Suzuki K, Ishihara A, Kubo-Irie M, Fujimoto R, Tabata M, Oshio S, Nihei Y, Ihara T, Sugamata M. Nanoparticles transferred from pregnant mice to their offspring can damage the genital and cranial nerve systems. J Health Sci 2009, 55:95-102.
67. Ma L, Liu J, Li N, Wang J, Duan Y, Yan J, Liu H, Wang H, Hong F. Oxidative stress in the brain of mice caused by translocated nanoparticulate TiO2 delivered to the abdominal cavity. Biomaterials 2010, 31:99-105. 10.1016/j.biomaterials.2009.09.028, 19783296.
68. Tang M, Li Z, Chen L, Xing T, Hu Y, Yang B, Ruan DY, Sun F, Wang M. The effect of quantum dots on synaptic transmission and plasticity in the hippocampal dentate gyrus area of anesthetized rats. Biomaterials 2009, 30:4948-55. 10.1016/j.biomaterials.2009.06.012, 19564038.
69. Maysinger D, Behrendt M, Lalancette-Hebert M, Kriz J. Real-time imaging of astrocyte response to quantum dots: in vivo screening model system for biocompatibility of nanoparticles. Nano Lett 2007, 7:2513-20. 10.1021/nl071611t, 17638392.
70. Pisanic TR, Blackwell JD, Shubayev VI, Finones RR, Jin S. Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials 2007, 28:2572-81. 10.1016/j.biomaterials.2007.01.043, 17320946.
71. Long TC, Tajuba J, Sama P, Saleh N, Swartz C, Parker J, Hester S, Lowry GV, Veronesi B. Nanosize titanium dioxide stimulates reactive oxygen species in brain microglia and damages neurons in vitro. Environ Health Perspect 2007, 115:1631-7. 10.1289/ehp.10216, 2072833, 18007996.
72. Alekseenko AV, Waseem TV, Fedorovich SV. Ferritin, a protein containing iron nanoparticles, induces reactive oxygen species formation and inhibits glutamate uptake in rat brain synaptosomes. Brain Res 2008, 1241:193-200. 10.1016/j.brainres.2008.09.012, 18835382.
73. Schubert D, Dargusch R, Raitano J, Chan SW. Cerium and yttrium oxide nanoparticles are neuroprotective. Biochem Biophys Res Commun 2006, 342:86-91. 10.1016/j.bbrc.2006.01.129, 16480682.
74. Sayes CM, Gobin AM, Ausman KD, Mendez J, West JL, Colvin VL. Nano-C60 cytotoxicity is due to lipid peroxidation. Biomaterials 2005, 26:7587-95. 10.1016/j.biomaterials.2005.05.027, 16005959.
75. Jin H, Chen WQ, Tang XW, Chiang LY, Yang CY, Schloss JV, Wu JY. Polyhydroxylated C(60), fullerenols, as glutamate receptor antagonists and neuroprotective agents. J Neurosci Res 2000, 62:600-7. 10.1002/1097-4547(20001115)62:4<600::AID-JNR15>3.0.CO;2-F, 11070504.
76. Dugan LL, Gabrielsen JK, Yu SP, Lin TS, Choi DW. Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons. Neurobiol Dis 1996, 3:129-35. 10.1006/nbdi.1996.0013, 9173920.
77. Hussain SM, Javorina AK, Schrand AM, Duhart HM, Ali SF, Schlager JJ. The interaction of manganese nanoparticles with PC-12 cells induces dopamine depletion. Toxicol Sci 2006, 92:456-63. 10.1093/toxsci/kfl020, 16714391.
78. Wang Z, Zhao J, Li F, Gao D, Xing B. Adsorption and inhibition of acetylcholinesterase by different nanoparticles. Chemosphere 2009, 77(1):67-73. 10.1016/j.chemosphere.2009.05.015, 19540550.
79. Wang Z, Zhang K, Zhao J, Liu X, Xing B. Adsorption and inhibition of butyrylcholinesterase by different engineered nanoparticles. Chemosphere 2010, 79:86-92. 10.1016/j.chemosphere.2009.12.051, 20089293.
80. Liu Z, Ren G, Zhang T, Yang Z. Action potential changes associated with the inhibitory effects on voltage-gated sodium current of hippocampal CA1 neurons by silver nanoparticles. Toxicology 2009, 264:179-84. 10.1016/j.tox.2009.08.005, 19683029.
81. Zhao J, Xu L, Zhang T, Ren G, Yang Z. Influences of nanoparticle zinc oxide on acutely isolated rat hippocampal CA3 pyramidal neurons. Neurotoxicology 2009, 30:220-30. 10.1016/j.neuro.2008.12.005, 19146874.
82. Xu LJ, Zhao JX, Zhang T, Ren GG, Yang Z. In vitro study on influence of nano particles of CuO on CA1 pyramidal neurons of rat hippocampus potassium currents. Environ Toxicol 2009, 24:211-7. 10.1002/tox.20418, 18623077.
83. Jakubek LM, Marangoudakis S, Raingo J, Liu X, Lipscombe D, Hurt RH. The inhibition of neuronal calcium ion channels by trace levels of yttrium released from carbon nanotubes. Biomaterials 2009, 30:6351-7. 10.1016/j.biomaterials.2009.08.009, 2753181, 19698989.
84. Powers CM, Wrench N, Ryde IT, Smith AM, Seidler FJ, Slotkin TA. Silver impairs neurodevelopment: studies in PC12 cells. Environ Health Perspect 2010, 118:73-9. 2831971, 20056586.
85. Liu X, Ren X, Deng X, Huo Y, Xie J, Huang H, Jiao Z, Wu M, Liu Y, Wen T. A protein interaction network for the analysis of the neuronal differentiation of neural stem cells in response to titanium dioxide nanoparticles. Biomaterials 2010, 31:3063-70. 10.1016/j.biomaterials.2009.12.054, 20071024.
86. Wu WH, Sun X, Yu YP, Hu J, Zhao L, Liu Q, Zhao YF, Li YM. TiO2 nanoparticles promote beta-amyloid fibrillation in vitro. Biochem Biophys Res Commun 2008, 373:315-8. 10.1016/j.bbrc.2008.06.035, 18571499.
87. Linse S, Cabaleiro-Lago C, Xue WF, Lynch I, Lindman S, Thulin E, Radford SE, Dawson KA. Nucleation of protein fibrillation by nanoparticles. Proc Natl Acad Sci USA 2007, 104:8691-6. 10.1073/pnas.0701250104, 1866183, 17485668.
88. Tang M, Wang M, Xing T, Zeng J, Wang H, Ruan DY. Mechanisms of unmodified CdSe quantum dot-induced elevation of cytoplasmic calcium levels in primary cultures of rat hippocampal neurons. Biomaterials 2008, 29:4383-91. 10.1016/j.biomaterials.2008.08.001, 18752844.